Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indicationsSOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE ...

The "Cell Therapy Processing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering. The global market for cell therapy processing is estimated to grow from $2.7 ...

Autolus Therapeutics, a commercial-stage biopharmaceutical company, has announced plans to assess the feasibility of Cellares ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

MaxCyte and Ori Biotech entered into a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. The collaboration combines the MaxCyte ...

Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of ...

This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the company is a “little late to join the party.” But just because AZ has trailed ...

Cell therapy manufacturing has long been constrained by manual bottlenecks - steps that are labor-intensive, variable, and difficult to scale. Robotic automation is increasingly becoming key to ...